Interim Phase 1 Safety Report Confirms Safety of ARG-007
Filed with ASX · · 5 pages · English
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- Non-Dilutive Funding Received to Progress Alzheimers Studies
- Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers
- Argenica Awarded $1.2m CRC-P Grant for TBI Project
- Successful Completion of Phase 1 Clinical Trial Dosing
- SRC Approves Commencement Of Fourth And Final Cohort Dosing
Later from Argenica Therapeutics
- Significant Non-Dilutive Funding For Preclinical HIE Studies
- Latest Preclinical HIE Study Results
- Final Phase1 Clinical Trial Report
- Argenica Successfully Completes $4.0m Placement
- ARG-007 Protects Brain Cells in Moderate TBI Model
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics